Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.

@article{Vakkalagadda2016EffectOR,
  title={Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa.},
  author={Blisse J Vakkalagadda and Charles E. Frost and Wonkyung Byon and Rebecca A. Boyd and Jessie Yi-jia Wang and Donglu Zhang and Zhigang Yu and Clapton Dias and Andrew Shenker and Frank P Lacreta},
  journal={American journal of cardiovascular drugs : drugs, devices, and other interventions},
  year={2016},
  volume={16 2},
  pages={119-27}
}
OBJECTIVE Apixaban is a substrate of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein. The effects of rifampin, a strong inducer of CYP3A4 and P-glycoprotein, on the pharmacokinetics of oral and intravenous apixaban were evaluated in an open-label, randomized, sequential crossover study. METHODS Twenty healthy participants received single doses of apixaban 5 mg intravenously on day 1 and 10 mg orally on day 3, followed by rifampin 600 mg once daily on days 5-15. Finally, participants received… CONTINUE READING